Platelet-mediated lymphocyte delivery to high endothelial venules

Science

Volumn 273, Issue 5272, 1996, Pages 252-255

  Diacovo, Thomas G ^a,b   Puri, Kamal D ^a   Warnock, R Aaron ^c   Springer, Timothy A ^a   Von Andrian, Ulrich H ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SELECTIN;

ADHESION; ARTICLE; ENDOTHELIUM; LYMPH NODE; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; VENULE;

EID: 0029794005     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5272.252     Document Type: Article

References (45)

1. T. A. Springer, Cell 76, 301 (1994); E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
2. T. A. Springer, Cell 76, 301 (1994); E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
3. W. M. Gallatin, I. L. Weissman, E. C. Butcher, Nature 304, 30 (1983).
4. P. R. Streeter, B. T. N. Rouse, E. C. Butcher, J. Cell Biol. 107, 1853 (1988).
5. E. L. Berg, M. K. Robinson, R. A. Warnock, E. C. Butcher, ibid. 114, 343 (1991).
6. Y. Imai, M. S. Singer, C. Fennie, L. A. Lasky, S. D. Rosen, ibid. 113, 1213 (1991).
7. E. L. Berg, L. M. McEvoy, C. Berlin, R. F. Bargatze, E. C. Butcher, Nature 366, 695 (1993).
8. M. B. Lawrence, E. L. Berg, E. C. Butcher, T. A. Springer, Eur. J. Immunol. 25, 1025 (1995).
9. S. A. Michie, P. R. Streeter, P. A. Bolt, E. C. Butcher, L. J. Picker, Am. J. Pathol. 143, 1688 (1993); J. P. Turunen et al., Eur. J. Immunol. 24, 1130 (1994).
10. S. A. Michie, P. R. Streeter, P. A. Bolt, E. C. Butcher, L. J. Picker, Am. J. Pathol. 143, 1688 (1993); J. P. Turunen et al., Eur. J. Immunol. 24, 1130 (1994).
11. C. E. Collins, M. R. Cahill, A. C. Newland, D. S. Rampton, Gastroenterology 106, 840 (1994).
12. Mice were anesthetized by intraperitoneal injection (0.2 ml) of a mixture of ketamine (5 mg/ml) and xylazine (1 mg/ml), and catheters were inserted into the right jugular vein (for injection of anesthesia and mAb), the left carotid artery (for blood pressure monitoring), and the right femoral artery (for retrograde injection of fluorescently labeled cells). Subsequently, the left subiliac LN was microsurgically prepared for intravital microscopy as described (U. H. von Andrian, Microcirculation, in press). The preparation was transferred to a custom-built intravital microscope (IV-500; Micron Instruments, San Diego, CA). For microscopic observation of endogenous microvascular WBC behavior, a bolus injection of sterile Ringer's lactate (10 ml per kilogram of body weight) containing the fluorescent dye rhodamine 6G (2 mg/ ml; Molecular Probes) was given intravenously. Rhodamine 6G stains nuclei and mitochondria in living cells, thereby permitting visualization of interacting and freely flowing leukocytes in LN HEVs by fluorescent stroboscopic epi-illumination through a 20× Zeiss objective. Video scenes were recorded through a low-lag SIT camera (Dage MTI) and stored on Hi 8 videotape for off-line analysis of rolling fractions, rolling velocities, and microvascular hemodynamics as described [U. H. von Andrian et al., Am. J. Physiol. 263, H1034 (1992)]. After a 3- to 5-min control recording of HEVs, some animals were treated with mAb Mel-14 [100 μg per mouse, intravenously (iv)], and leukocyte behavior in the same vascular bed was recorded 15 min later.
13. Mice were anesthetized by intraperitoneal injection (0.2 ml) of a mixture of ketamine (5 mg/ml) and xylazine (1 mg/ml), and catheters were inserted into the right jugular vein (for injection of anesthesia and mAb), the left carotid artery (for blood pressure monitoring), and the right femoral artery (for retrograde injection of fluorescently labeled cells). Subsequently, the left subiliac LN was microsurgically prepared for intravital microscopy as described (U. H. von Andrian, Microcirculation, in press). The preparation was transferred to a custom-built intravital microscope (IV-500; Micron Instruments, San Diego, CA). For microscopic observation of endogenous microvascular WBC behavior, a bolus injection of sterile Ringer's lactate (10 ml per kilogram of body weight) containing the fluorescent dye rhodamine 6G (2 mg/ ml; Molecular Probes) was given intravenously. Rhodamine 6G stains nuclei and mitochondria in living cells, thereby permitting visualization of interacting and freely flowing leukocytes in LN HEVs by fluorescent stroboscopic epi-illumination through a 20× Zeiss objective. Video scenes were recorded through a low-lag SIT camera (Dage MTI) and stored on Hi 8 videotape for off-line analysis of rolling fractions, rolling velocities, and microvascular hemodynamics as described [U. H. von Andrian et al., Am. J. Physiol. 263, H1034 (1992)]. After a 3- to 5-min control recording of HEVs, some animals were treated with mAb Mel-14 [100 μg per mouse, intravenously (iv)], and leukocyte behavior in the same vascular bed was recorded 15 min later.
14. R. A. Warnock, E. C. Butcher, U. H. von Andrian, unpublished data.
15. Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
16. Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
17. Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
18. T. G. Diacovo and U. H. von Andrian, data not shown.
19. G. I. Johnston, R. G. Cook, R. P. McEver, Cell 56, 1033 (1989).
20. T. N. Mayadas, R. C. Johnson, H. Raybum, R. O. Hynes, D. D. Wagner, ibid. 74, 541 (1993).
21. K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
22. K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
23. K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
24. K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
25. P. S. Frenette, R. C. Johnson, R. O. Hynes, D. D. Wagner, Proc. Natl. Acad. Sci. U.S.A. 92, 7450 (1995).
26. D. Sako et al., Cell 75, 1179 (1993).
27. K. L. Moore et al., J. Cell Biol. 128, 661 (1995).
28. 7 per milliliter), and injected into mice as described (12).
29. K. D. Puri, E. B. Finger, G. Gaudemack, T. A. Springer, J. Cell Biol. 131, 261 (1995).
30. S. Baumhueter et al., Science 262, 436 (1993); L. A. Lasky et al., Cell 69, 927 (1992).
31. S. Baumhueter et al., Science 262, 436 (1993); L. A. Lasky et al., Cell 69, 927 (1992).
32. T. Diacovo et al., J. Exp. Med. 183, 1193 (1996).
33. T. K. Kishimoto, M. A. Jutila, E. C. Butcher, Proc. Natl. Acad. Sci. U.S.A. 87, 2244 (1990).
34. C. Foxall et al., J. Cell Biol. 117, 895 (1992); R. E. Mebius and S. R. Watson, J. Immunol. 151, 3252 (1993).
35. C. Foxall et al., J. Cell Biol. 117, 895 (1992); R. E. Mebius and S. R. Watson, J. Immunol. 151, 3252 (1993).
36. U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
37. U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
38. U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
39. H.-A. Lehr et al., Lab. Invest. 71, 380 (1994); H.-A. Lehr, B. Frei, K.-E. Arfors, Proc. Natl. Acad. Sci. U.S.A. 91, 7688 (1994).
40. H.-A. Lehr et al., Lab. Invest. 71, 380 (1994); H.-A. Lehr, B. Frei, K.-E. Arfors, Proc. Natl. Acad. Sci. U.S.A. 91, 7688 (1994).
41. B. Savage, E. Saldivar, Z. M. Ruggeri, Cell 84 (1996).
42. A. R. Pries, Int. J. Microcirc. Clin. Exp. 7, 327 (1988); K. Ley and P. Gaehtgens, Circ. Res. 69, 1034 (1991).
43. A. R. Pries, Int. J. Microcirc. Clin. Exp. 7, 327 (1988); K. Ley and P. Gaehtgens, Circ. Res. 69, 1034 (1991).
44. U. H. von Andrian, S. R. Hasslen, R. D. Nelson, S. L. Erlandsen, E. C. Butcher, Cell 82, 1 (1995).
45. We thank B. Fors, E. Finger, and G. Cheng for technical assistance; E. Butcher, P. Newman, D. Wagner, G. Gaudernack, and R. McEver for contributing reagents; and K. Gauvreau for aiding in statistical analysis. Supported by National Institutes of Health grants HL48675 and HL54936.